NextPlat (NXPL)
Sells satellite connectivity products online while operating pharmacy and healthcare-data services.
$9.22
At close−0.42 (−4.36%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15 | 17 | 17 | 17 | 15 | 16 | 15 | 13 | 14 | 13 | 10 | 12 |
| Cost of revenue | 11 | 15 | 13 | 11 | 12 | 14 | 11 | 10 | 11 | 11 | 6 | 7 |
| Gross profit | 5 | 2 | 5 | 6 | 4 | 2 | 3 | 3 | 3 | 2 | 3 | 5 |
| 8 | 3 | 7 | 17 | 12 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | |
| 4 | 3 | 6 | 6 | 7 | 5 | 5 | 5 | 5 | 5 | 2 | 5 | |
| Selling & marketing | 4 | −3 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 1 | 6 | 6 | 1 | 7 | 5 | 5 | 5 | 5 | 5 | 2 | 5 |
| Other expenses | 4 | 0 | 1 | 11 | 4 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| Operating income | −3 | −1 | −2 | −11 | −8 | −3 | −1 | −2 | −2 | −3 | −1 | 0 |
| −1 | −8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −2 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Income before tax | −4 | −10 | −2 | −11 | −8 | −3 | −1 | −2 | −2 | −5 | −1 | 0 |
| Income tax expense | −7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Net income from continuing operations | 3 | −10 | −2 | −11 | −8 | −3 | −1 | −2 | −2 | −6 | −1 | 0 |
| Net income | 3 | −2 | −1 | −5 | −4 | −3 | −1 | −2 | −2 | −6 | −1 | 0 |
| EPS, basic | $1.80 | −$0.91 | −$0.79 | −$2.80 | −$2.20 | −$1.20 | −$0.52 | −$0.69 | −$0.84 | −$2.50 | −$0.42 | −$0.05 |
| EPS, diluted | $1.80 | −$0.91 | −$0.79 | −$2.80 | −$2.20 | −$1.20 | −$0.52 | −$0.69 | −$0.84 | −$2.50 | −$0.42 | −$0.05 |
| Weighted average shares, basic | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Weighted average shares, diluted | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| EBITDA | −2 | −14 | −1 | −10 | −7 | −3 | −1 | −1 | −2 | −5 | −1 | 0 |
| Depreciation & amortization | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −3 | −15 | −2 | −11 | −8 | −3 | −1 | −2 | −2 | −5 | −1 | 0 |
